Analyst Reco. Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
1.215 ^USD	+19.12%		+16.83%	+65.31%

Mar. 06	Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alliance Global Initiates AcelRx Pharmaceuticals at Buy With $4.25 Price Target	23-10-02	MT
HC Wainwright Adjusts AcelRx Pharmaceuticals Price Target to $5 From $8, Maintains Buy Rating	23-09-25	MT
HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8	23-08-18	MT
HC Wainwright Downgrades AcelRx Pharmaceuticals to Neutral from Buy	22-03-14	MT
Cantor Fitzgerald Lowers Price Target for AcelRx Pharmaceuticals to $4 From $9, Maintains Overweight Rating	21-12-01	MT
ACELRX PHARMACEUTICALS : HC Wainwright Adjusts Price Target on AcelRx Pharmaceuticals to $5 From $7, Maintains Buy Rating	21-08-17	MT
AcelRx Pharmaceuticals, Inc. Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of Dsuvia for Acute Pain in Hospital Settings	21-03-25	CI
ACELRX PHARMACEUTICALS : Credit Suisse Adjusts AcelRx Pharmaceuticals' Price Target to $0.83 From $0.84, Reiterates Underperform Rating	20-11-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW